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Abstract
Background: Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme for producing g-aminobutyric acid,
and it has been suggested that antibodies against GAD play a role in neurological conditions and type 1 diabetes.
However, it is not known whether dementia appears as the sole neurological manifestation associated with anti-
GAD antibodies in the central nervous system.
Case presentation: We describe the clinical, neuropsychological, and neuroradiological findings of a 73-year-old
female with cognitive dysfunction and type 1A diabetes. Observation and neuropsychological studies revealed
linguistic problems, short-term memory disturbance, and frontal dysfunction. MRI showed no significant lesion
except for confluent small T2-hyperintensity areas localized in the left basal ganglia.
18F-fluorodeoxy glucose-
positron emission tomography (FDG-PET) and
123I-N-isopropyl-p-iodoamphetamine-single photon emission
computed tomography (IMP-SPECT) studies showed bifrontal hypometabolism and hypoperfusion.
Immunomodulating therapy with intravenous high-dose immunoglobulin resulted in no remission of the cognitive
symptoms.
Conclusions: Cognitive dysfunction may develop as an isolated neurological manifestation in association with type
1A diabetes and anti-GAD autoimmunity. A systematic study with extensive neuropsychological assessment is
indicated in patients with type 1 diabetes and anti-GAD autoimmunity.
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Background
Glutamic acid decarboxylase (GAD) is the biosynthesiz-
ing enzyme of the neurotransmitter g-aminobutyric acid
(GABA). Antibodies against GAD cause neurological
syndromes[1], including stiff person syndrome (SPS)[2],
cerebellar ataxia[3], and limbic encephalitis[4] as well as
type 1 diabetes[5]. Behavioral and cognitive problems
may be associated with SPS[6], limbic encephalitis[7], or
cerebellar ataxia, and some of the psychiatric symptoms
that have been reported in SPS[8] are considered to be
related to dysfunction of the GABAergic system. How-
ever, it is not known whether dementia appears as the
sole neurological manifestation associated with anti-
GAD antibodies in the central nervous system. We
report here a patient with GAD autoimmunity and type
1A diabetes who developed cognitive impairment with-
out known anti-GAD-related neurological conditions.
Case Presentation
A 73-year-old, right-handed, high school-educated Japa-
nese housewife developed polydipsia, polyuria, progres-
sive weight loss, and increasing fatigue in the summer
of 2008. A diagnosis of type 1 diabetes was made, and
the patient was admitted to our hospital in February
2009 to control her diabetes. The attending physician
and nurses in the ward noticed that she had difficulty
mastering insulin self-injection, and she was referred to
us for evaluation of possible dementia. She lived inde-
pendently, and she and her family had not noticed
memory problems in her daily life. She had no history
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any medium, provided the original work is properly cited.of cigarette smoking, alcohol abuse, or neurological/psy-
chiatric illness. A detailed review of the family history
was unremarkable for neurologic/psychiatric illness.
On examination, the patient was oriented to place, but
not to time. There were no signs of mood disorders,
psychiatric illness, or changes in personality or social
conduct. The neurological examination was unremark-
able; the only faint abnormality we detected was an irre-
gular saccadic eye movement on lateral gaze with
difficulty maintaining rightward gaze.
The results of routine laboratory tests were all within
normal limits except for mild hyperglycemia (serum glu-
cose 128 mg/dl, HbA1c 7.2%). Her thyroid function was
normal, and her serum levels of vitamin B1 and B12
were also normal. The serological studies indicated high
titers of anti-GAD (2865.2 U/ml), anti-insulinoma asso-
ciated protein (IA)-2 (45.1 U/ml), anti-thyroid peroxi-
dase (14.5 U/ml), and anti-thyroglobulin (67.8 U/ml)
antibodies. Her cerebrospinal fluid (CSF) was negative
for hypercellularity, oligoclonal bands, or myelin basic
protein. Her CSF was positive for anti-GAD antibodies
(60.1 U/ml). The antibody specificity index (ASI = [anti-
GADCSF/IgGCSF]/[anti-GADserum/IgGserum], which
measures the intrathecal synthesis of anti-GAD antibo-
dies[9,10]) was 3.16, while the IgG index was 0.53.
The thoracic, abdominal, and pelvic CT scans showed
no evidence of malignancy. An MRI of the head did not
demonstrate any abnormalities other than a small and
questionable lesion showing T2-hyperintensity not asso-
ciated with T1-hypointensity in the left putamen (Figure
1). Specifically, there was no evidence of atrophy of the
medial temporal lobes. The functional neuroimaging,
18F-fluorodeoxy glucose-positron emission tomography
(FDG-PET) indicated bifrontal cortical hypometabolism
(Figure 2) and
123I-N-isopropyl-p-iodoamphetamine-
single photon emission computed tomography (IMP-
SPECT) showd concomitant hypoperfusion. Carotid
Doppler ultrasonography showed mild atherosclerotic
change with a maximum intima-media thickening of 2.0
mm. The EEG showed mild general slowing and bilat-
eral temporal delta-range activity.
Table 1 summarizes the results of the neuropsycholo-
gical tests. The patient’ speech was fluent, and her
articulation and prosody were normal. There were few
literal and semantic paraphasias. However, she had
apparent language problems characterized by defective
auditory comprehension and defective repetition. Her
score on the Japanese version of the Western Aphasia
Battery AQ was 78.4. Her language problems were also
apparent when comparing her WAIS-III verbal IQ to
her relatively preserved performance IQ. Her executive
functions were also defective; the verbal fluency, Trail
making-B, and WAIS III working memory sub-items
indicated low performance, while her processing speed
was preserved. The memory tests revealed that the
patient was mildly amnestic. Her recognition memory
was relatively preserved.
A five-day course of high-dose (0.4 g/kg/day) intrave-
nous immunoglobulin (IVIg) was implemented after
written informed consent was obtained. However, the
symptoms, neuropsychological profile, and insulin
dependence remained unchanged immediately after the
treatment. Her anti-GAD antibody titers also remained
high, both in her serum (2832.5 U/ml) and CSF (75.4
U/ml). No further treatment was implemented due to
her withdrawal of consent. The status of her diabetes
has been stable for one and a half years. No progression
of neurological impairment has been demonstrated in
daily life, on the neuropsychological tests, and on neu-
roimagings during this period.
Figure 1 The brain MRI findings. The axial fluid-attenuated inversion recovery (FLAIR) images showed a small hyperintense lesion in the left
putamen. Neither generalized nor focal cortical atrophy suggestive of Alzheimer disease or other degenerative dementias was noted.
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We have described here a type 1 diabetic, anti-GAD
antibody-positive patient who presented with cognitive
impairment characterized by language disturbance, ver-
bal short-term (working) memory disturbance, executive
dysfunction, and mild amnesia with spared recognition
memory as an isolated symptom. Although behavioral
and cognitive impairments may also accompany anti-
GAD-related neurological disorders, including cerebellar
ataxia and limbic encephalitis, no signs of these disor-
ders were detected in the patient. The cognitive impair-
ment is of features of frontal lobe involvement, which
was not improved significantly after a single course of
high-dose IVIg treatment, although no further progres-
sion was noted thereafter over 18 months.
The non-progressive time course of the cognitive
decline is not supportive of neurodegenerative diseases,
and the features of the cognitive impairment and of
neuroimaging findings are not compatible with Alzhei-
mer diseases, the commonest cause of dementia in the
patient’s age, although it can not be completely ruled
out. The small lesion restricted in the left putamen
shown by the MRI is unlikely to be causative of the cog-
nitive impairment, as the putamen is not a strategic site
interrupting frontal-subcortical circuits for behavior and
cognition [11].
Recent studies have demonstrated that cognitive
decline is associated with type 1 diabetes. A meta-analy-
sis[12] has indicated that type 1 diabetes-related cogni-
tive dysfunction is characterized by decreased mental
speed and mental flexibility with spared learning and
memory, which is consistent with the cognitive impair-
ment of our patient. Although the underlying mechan-
isms remain to be elucidated, cognitive impairment
related to frontal lobe dysfunction may occur in patients
with type 1 diabetes. Increased risk for cerebrovascular
diseases in diabetic patients is generally accepted to be
attributable to the cognitive decline of features of frontal
involvement in those patients. Anti-GAD immunity has
not been considered to be directly causative of cognitive
decline in type 1 diabetics. Meanwhile, our patient was
positive for anti-GAD antibody in CSF, which made us
infer some possible autoimmune process occurred in
cerebrum resulting in cognitive dysfunction. A recent
study has revealed that high anti-GAD antibody levels
(more than 2000 U/ml) are associated with a spectrum
of neurological syndrome[1], and that the intrathecal
synthesis of anti-GAD antibodies plays an important
role in the development of neurological disorders. In
our patient, the serum anti-GAD antibody level was as
high as that of SPS patients, and the ASI for anti-GAD
antibodies exceeded the IgG index and the normal
range[9], which supports anti-GAD autoimmunity as the
potential cause of the cerebral involvement.
Immunomodulating therapies are reportedly effective
for anti-GAD autoimmunity -associated neurological
manifestations [4,7,13,14]. A single case report described
a patient with Stiff-person plus syndrome[15] in whom
anxious depression was improved after corticosteroid
treatment. Although a few case reports showed that
neurological manifestations are along with decrease of
anti-GAD antibody titer, no correlation was noted
Figure 2 The FDG PET scans of the patient. Bilateral frontal lobe hypometabolism was noted.
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magnitude of clinical response in a controlled study, in
which a three-month course of high-dose IVIg demon-
strated benefits in SPS patients [16]. Therefore, it is dif-
ficult to discuss the relationship between the failure of
serological and clinical response after high-dose IVIg in
our patient. Although an optimal treatment for GAD
anti-immunity has not been established, high-dose IVIg
seemed to be most promising at least for SPS. Monthly
repetitive administration of 2 g/kg immunoglobulin
divided into two daily doses (i.e., 1 mg/day × 2) has
been originally recommended, and the response report-
edly appears after repeated dosages of several months.
We followed the recommendation for the treatment of
neuromuscular disease in our country, the same dosage
divided into five daily doses (i.e., 0.4 mg/day × 5), to
minimize infusion reactions. As we could give only one
course of IVIg because of the patient’s refusal, we can-
not conclude whether the treatment is ineffective or
insufficient.
Conclusion
Our patient suggests that dementia occurs as a potential
isolated neurological manifestation of anti-GAD autoim-
munity, and that anti-GAD autoimmunity is a possible
cause of cognitive decline in patients with type 1 dia-
betes. As cognitive decline is a common, rather nonde-
script symptom, a systematic study with extensive
neuropsychological assessment would be indicated in
patients with anti-GAD autoimmunity and type 1
diabetes.
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Table 1 The Patient’s Neuropsychological Profile
General Intelligence
Wechsler Adult Intelligence Scale-3rd edition
Full Scale IQ 70
Verbal IQ 66
Performance IQ 80
Verbal Comprehension 66
Perceptual Organization 77
Working Memory 67
Processing Speed 102
Attention
Digit Span
Forward 3
Backward 3
Tapping Span
Forward 4
Backward 2
Wechsler Memory Scale-Revised
Attention/Concentration (index) 53
Language
Western Aphasia Battery
Aphasia Quotient 78.4
Memory
Wechsler Memory Scale-Revised
General Memory 64
Delayed Recall 63
Rey Osterrieth Complex Figure Test
Immediate Recall 10.5/30
Recognition 19/24
Rey Auditory Verbal Learning Test
Total recall during trial 1-5 23/75
Recognition 11/15
Visuoperceptual Ability
Cube copy perfect
Rey Osterrieth Complex Figure Test
Copy 36/36
Executive Function
Verbal Fluency Test
Category (Animal) 11
Phoneme (fu, a, ni) 3,5,3
Trail Making part A 62 sec
Trail Making part B 249 sec
Nonverbal Reasoning
Raven Colored Progressive Matrices Test 24/36
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